Gracell Biotechnologies

Gracell Biotechnologies, Inc. engages in the research and development activities of biotechnological and pharmaceutical industries. The firm through its FasTCAR and TruUCAR platforms, it is developing a pipeline of autologous and allogeneic cell therapy candidates with the potential to treat both hematologic malignancies and solid tumors. The company was founded by William Wei Cao in 2017 and is headquartered in Suzhou, China.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 22, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, Nasdaq: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune disease, today announced the completion of its previously announced agreement to be acquired by AstraZeneca, in accordance with the terms and conditions of the Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub (“Merger Sub”), an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent. The acquisition was structured as a merger of Merger Sub with and into the Company with the Company surviving the merger as a wholly owned subsidiary of Parent (the “Merger”). As a result of the Merger, the Company ceased to be a publicly traded company and became a wholly owned subsidiary of Parent.

Gracell Biotechnologies Acquisition Completed

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that at an extraordinary general meeting of shareholders (the “EGM”) held on February 19, 2024, the Company's shareholders voted in favor of the proposal to approve and authorize the execution, delivery and performance by the Company of the previously announced Agreement and Plan of Merger, dated as of December 23, 2023 (the “Merger Agreement”), by and among the Company, AstraZeneca Treasury Limited, a private limited company incorporated under the laws of England and Wales (“Parent”), and Grey Wolf Merger Sub, an exempted company with limited liability incorporated under the laws of the Cayman Islands and a wholly owned subsidiary of Parent (“Merger Sub”), the Plan of Merger required to be filed with the Registrar of Companies of the Cayman Islands (the “Plan of Merger”), and the other agreements or documents contemplated by the Merger Agreement or any document or instrument delivered in connection thereunder (the “Transaction Documents”) to which the Company is a party and the consummation of the transactions contemplated by the Merger Agreement (including the Merger) and the Contingent Value Rights Agreement, in the form attached as Exhibit B to the Merger Agreement, (collectively, the “Transactions”), upon the terms and subject to the conditions set forth therein. Pursuant to the Merger Agreement, in accordance with the applicable provisions of the Companies Act (As Revised) of the Cayman Islands, Merger Sub will merge with and into the Company at the effective time of the Merger, with the Company continuing as the surviving company and becoming a wholly owned subsidiary of the Parent (the “Merger”).

Gracell Biotechnologies Announces Shareholders' Approval of Merger Agreement

Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma Further expands clinical development of FasTCAR-T GC012F in multiple myeloma amid ongoing U.S. trial evaluating therapy for treatment of relapsed/refractory multiple myeloma

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1 Clinical Trial of FasTCAR-T GC012F as Early-Line Treatment of Multiple Myeloma

Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) have what it takes to be a top stock pick for momentum investors? Let's find out.

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) is a Great Momentum Stock: Should You Buy?

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Gracell Biotechnologies Inc. (NasdaqGS: GRCL) to AstraZeneca. Under the terms of the proposed transaction, shareholders of Gracell will receive $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (.

GRACELL BIOTECHNOLOGIES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Gracell Biotechnologies Inc. - GRCL

AstraZeneca

Dec 26 (Reuters) - AstraZeneca (AZN.L) said on Tuesday it will buy Gracell Biotechnologies (GRCL.O) for up to $1.2 billion as the Anglo-Swedish pharma company furthers its cell therapy ambitions and boosts its presence in China, the world's second-largest pharmaceuticals market.

AstraZeneca to buy China's Gracell Biotechnologies in $1.2 billion deal

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Gracell Biotechnologies Inc. (NASDAQ: GRCL) to AstraZeneca is fair to Gracell shareholders. Under the terms of the proposed transaction, AstraZeneca will acquire Gracell for $2.00 per ordinary share in cash at closing (equivalent to $10.00 per ADS of Gracell), plus a non-tradable contingent value right of $0.30 per ordinary share in cash (equivalent to $1.50 per ADS of Gracell) payable.

GRCL Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Gracell Biotechnologies Inc. Is Fair to Shareholders

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca has entered into a definitive agreement to acquire Gracell Biotechnologies Inc. (Gracell, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company developing innovative cell therapies for the treatment of cancer and autoimmune diseases, furthering the AstraZeneca cell therapy ambition. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual.

AstraZeneca to acquire Gracell, furthering cell therapy ambition across oncology and autoimmune diseases

Proposed acquisition will enrich the AstraZeneca cell therapy pipeline with clinical-stage autologous BCMA/CD19 CAR-T therapy targeting haematologic malignancies and autoimmune diseases, and proprietary cell therapy manufacturing platform Gracell shareholders to receive $2.00 per ordinary share (equivalent to $10.00 per American Depositary Share (ADS)) in cash at closing, plus a non-tradable contingent value right (CVR) for up to $0.30 per ordinary share (equivalent to $1.50 per ADS), representing a total transaction value of up to $1.2 billion including the CVR SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 26, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative cell therapies for the treatment of cancer and autoimmune diseases, today announced it has entered into a definitive agreement to be acquired by AstraZeneca. The proposed acquisition will enrich AstraZeneca's growing pipeline of cell therapies with GC012F, a novel, clinical-stage FasTCAR-enabled BCMA and CD19 dual-targeting autologous chimeric antigen receptor T (CAR-T) cell therapy, a potential new treatment for multiple myeloma, as well as other haematologic malignancies and autoimmune diseases including systemic lupus erythematosus (SLE).

Gracell Biotechnologies to be acquired by AstraZeneca, furthering cell therapy ambition across oncology and autoimmune diseases

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.

Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Is a Great Choice for 'Trend' Investors, Here's Why

Expands clinical development of GC012F in rSLE following FDA IND clearance for Phase 1/2 trial in the United States Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in rSLE, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells FasTCAR-T GC012F has demonstrated a favorable safety profile in clinical investigator-initiated trials in 60 patients with multiple myeloma and B-cell non-Hodgkin lymphoma SAN DIEGO and SUZHOU, China and SHANGHAI, China, Dec. 21, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has cleared Gracell's Investigational New Drug (IND) application for GC012F, an autologous CAR-T therapeutic candidate, for the treatment of refractory systemic lupus erythematosus (rSLE). Under the IND, Gracell plans to initiate a Phase 1/2 clinical study in China to further evaluate GC012F in rSLE patients.

Gracell Biotechnologies Announces China NMPA Clearance for IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

Minimal residual disease negativity (MRD-) observed in all treated patients in the ongoing study, with 95% (21/22) achieving stringent complete response (sCR) through a median follow-up of 18.8 months

Gracell Biotechnologies Presents Updated Clinical Data from FasTCAR-T GC012F Demonstrating Deep and Durable Responses in Newly Diagnosed Multiple Myeloma at ASH 2023

The mean of analysts' price targets for Gracell Biotechnologies Inc. Sponsored ADR (GRCL) points to a 127.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Could Rally 127.82%: Here's is How to Trade

Gracell is pioneering use of a CD19/BCMA dual-targeted CAR-T cell therapy in refractory systemic lupus erythematosus, aiming for deeper and wider depletion of disease-causing antibody secreting cells and B-cells

Gracell Biotechnologies Announces FDA Clearance of IND Application for Phase 1/2 Clinical Trial of FasTCAR-T GC012F for the Treatment of Refractory Systemic Lupus Erythematosus

What Makes Gracell Biotechnologies Inc. Sponsored ADR (GRCL) a Strong Momentum Stock: Buy Now?

The consensus price target hints at a 120.9% upside potential for Gracell Biotechnologies Inc. Sponsored ADR (GRCL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Does Gracell Biotechnologies Inc. Sponsored ADR (GRCL) Have the Potential to Rally 120.94% as Wall Street Analysts Expect?

Presentation to focus on application of next-generation CAR-T cell therapy technologies for treatment of autoimmune disease

Gracell Biotechnologies to Participate in Inaugural Cell Therapy for Autoimmune Disease Summit

Gracell Biotechnologies Inc. (NASDAQ:GRCL ) Q3 2023 Earnings Conference Call November 13, 2023 8:00 AM ET Company Participants William Cao - Chairman and CEO Wendy Li - Chief Medical Officer Kevin Xie - CFO Conference Call Participants Yigal Nochomovitz - Citi Benjamin Burnett - Stifel Dev Prasad - Jefferies Eric Schmidt - Cantor Emily Bodnar - H.C. Wainwright Yanan Zhu - Wells Fargo Securities Joseph Catanzaro - Piper Sandler Justin Zelin - BTIG Operator Ladies and gentlemen, thank you for standing by.

Gracell Biotechnologies Inc. (GRCL) Q3 2023 Earnings Call Transcript

SAN DIEGO, Calif. and SUZHOU and SHANGHAI, China, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported third quarter unaudited financial results for the period ended September 30, 2023, and provided corporate updates.

Gracell Biotechnologies Reports Third Quarter 2023 Unaudited Financial Results and Provides Corporate Update

Gracell Biotechnologies (GRCL) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Should You Buy Gracell Biotechnologies (GRCL) Ahead of Earnings?

Arcellx

Eyenovia

Legend Biotech

Let us look at a few biotech companies, ACLX, LEGN, GRCL and EYEN, which are poised to beat third-quarter earnings estimates.

4 Biotech Stocks Likely to Outpace Q3 Earnings Estimates

Third annual BioTech Breakthrough Award recognizes excellence in life science and biotechnology solutions, services and companies

Gracell Biotechnologies Wins Overall Immunology Solution of the Year by BioTech Breakthrough Awards Program

Oral presentation of the updated results from ongoing Phase 1 investigator-initiated study of GC012F in frontline setting for transplant-eligible, high-risk newly diagnosed multiple myeloma

Gracell Biotechnologies to Present Updated Results from BCMA/CD19 Dual-Targeting FasTCAR-T GC012F in Newly Diagnosed Multiple Myeloma at the 65ᵗʰ American Society of Hematology Annual Meeting & Exposition

SAN DIEGO and SUZHOU, China and SHANGHAI, China, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. ("Gracell" or the "Company", NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, today announced that the management team will participate in four upcoming investor conferences in November. Stifel 2023 Healthcare Conference Fireside Chat: Tuesday, November 14th at 1:15 pm ETOne-on-one meetings: November 14th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York Jefferies London Healthcare Conference Fireside Chat: Wednesday, November 15th at 11:30 am GMT / 6:30 am ETOne-on-one meetings: November 15th and 16th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: London Piper Sandler 35 th Annual Healthcare Conference Presentation: Tuesday, November 28th at 12:00 pmOne-on-one meetings: November 28th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: New York 6th Annual Evercore ISI HealthCONx Conference Presentation: Wednesday, November 29th at 9:35 am ETOne-on-one meetings: November 29th and 30th, 2023Presenter: Dr. Kevin Xie, Chief Financial OfficerLocation: Miami Available webcasts of the presentations will be posted on the News and Events section of the Company's website.

Gracell Biotechnologies to Participate in Four Upcoming Investor Conferences

Novel, proprietary technology designed to strengthen the functionality of CAR-T cells against solid tumors SMART CAR-T cells demonstrated resistance to immunosuppressive tumor microenvironment (TME) and maintained long-term proliferation and cytotoxicity both in vitro and in vivo Launching investigator-initiated trial (IIT) of SMART CART GC506 targeting Claudin 18.2 positive tumors SAN DIEGO and SUZHOU, China and SHANGHAI, China, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Gracell Biotechnologies Inc. (“Gracell” or the “Company”, NASDAQ: GRCL), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune disease, announced today preclinical data from the Company's SMART CART™* technology for solid tumors will be presented as a poster at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place November 1-5, 2023, in San Diego and online. “Gracell has long been dedicated to unlocking the tremendous potential of CAR-T therapy against solid tumors in our pursuit of transformative cell therapies.

Gracell Biotechnologies to Present Data Highlighting Preclinical Efficacy of SMART CART™ Against Solid Tumors at Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

News for Gracell Biotechnologies Stock (GRCL)